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Although impaired immune regulation along the mucosa-bone marrow axis has been postulated to play an important role, the
pathogenesis of IgA nephropathy (IgAN) is unknown; thus, no disease-speciﬁc therapy for this disease exists. The therapeutic
eﬃcacy of tonsillectomy or tonsillectomy in combination with steroid pulse therapy for IgAN has been discussed. Although
randomized control trials for these therapies are ongoing in Japan, the scientiﬁc rationale for these therapies remains obscure.
It is now widely accepted that abnormally glycosylated IgA1 and its related immune complex (IC) are probably key molecules
for the pathogenesis, and are thus considered possible noninvasive biomarkers for this disease. Emerging evidence indicates that
B cells in mucosal infections, particularly in tonsillitis, may produce the nephritogenic IgA. In this paper, we brieﬂy summarize
characteristics of the nephritogenic IgA/IgA IC, responsible B cells, and underlying mechanisms. This clinical and experimental
information may provide important clues for a therapeutic rationale.
1.Introduction
IgA nephropathy (IgAN) is the most common form of
glomerulonephritis (GN) globally, accounting for 25%–50%
of primary GN patients [1]. Long-term follow-up studies
have shown that up to 25%–30% of IgAN patients progress
to end-stage kidney disease within 20–25 years [2]. However,
the pathogenesis of IgAN remains unclear, and consequently,
no disease-speciﬁc therapy for IgAN exists.
The recurrence of IgA deposition in renal allografts [3]
and the disappearance of IgA deposits from renal allografts
taken from donors with undiagnosed IgAN [4, 5] reinforce
the importance of systemic abnormalities of the IgA immune
system in IgAN, arguing against IgAN being a disease limited
to intrinsic renal abnormalities. Several clinical studies have
identiﬁed the importance of IgA or IgA-IC deposition as a
fundamental causative factorin IgAN [6]. The observed clin-
icopathological heterogeneity may, at least in part, be depen-
dent on the characteristics of the deposited IgA-IC itself or
changes in the IgA immune system, including sites of IgA
synthesis and stimulation and regulation of immunecompe-
tent cells involved in the production of IgA [7].
On the other hand, the episodic macrohematuria, coin-
ciding with mucosal infection such as tonsillitis and pharyn-
gitis [8] or an abnormal response to mucosal vaccination
in IgAN patients [9, 10], indicates that dysregulation of the
mucosal immune system may play an important role in the
pathogenesis of IgAN [6]. In addition, tonsillectomy is eﬀec-
tive in long-term renal survival in IgAN patients [11]. Some
Japanese studies have recently reported that tonsillectomy
in combination with steroid pulse therapy can be a more
eﬀective therapy for IgAN than tonsillectomy alone [12–14].
However, the therapeutic validity of tonsillectomy and
the indication for tonsillectomy for IgAN are controver-
sial [15–17], even in Japan. Although tonsillectomy in
certain patients can be an eﬀective therapy, 7%–10% of
IgAN patients show spontaneous clinical remission [18].
Therefore, a rationale and reasonable clinical markers are
needed for indication of this therapy. Recent studies show
that predictive factors for resistance to tonsillectomy in
combination with steroid pulse therapy are age of onset,
severity of proteinuria and hematuria, and pathological
grade [19]. Although there is an ongoing randomized
control trial evaluating the eﬀect of tonsillectomy on this2 Clinical and Developmental Immunology
disease, mainly by the Special Study Group on Progressive
Glomerular Disease of the Ministry of Health, Labor, and
Welfare of Japan and the Japanese Society of Nephrology, the
results are not yet available.
Many reports demonstrate that tonsillectomy is an eﬀec-
tive therapy for dermatological diseases such as pustulosis
palmaris et plantaris and psoriasis, sternocostoclavicular
hyperostosis, and rheumatoid arthritis [20–23]; the rationale
for this eﬀect is also unknown. In contrast, elucidation
of the rationale in IgAN may provide conclusive clues for
the pathogenesis of not only IgAN but also the so-called
“tonsillar focal infectious diseases.” To assess that rationale,
webrieﬂysummarizethecharacteristicsofnephritogenicIgA
and the B cells responsible for producing the nephritogenic
IgA.
2. Generation of Nephritogenic IgA in the
Mucosa-Bone Marrow(BM) AxisinIgAN
High levels of higher molecular forms of IgA are present in
the serum of IgAN patients [2, 6, 7]. In addition, it is gen-
erally accepted that IgA deposits in glomerular mesangium
primarilyconsistofpolymericformsofIgA1includingIC[2,
6, 7, 24]. Large numbers of polymeric IgA- (pIgA-) positive
p l a s m ac e l l sa r ef o u n di nB Mi nI g A N[ 6, 7, 25]. Moreover,
BM transplantation (BMT) in leukemia and IgAN patients
has resulted in curing not only of leukemia but also of IgAN
[26, 27], suggesting that overproduction of nephritogenic
pIgA1 in IgAN seems to be partly based in systemic immune
sites, such as BM. Furthermore, mucosal vaccination results
inimpairedmucosalIgAresponsesinIgANwhereassystemic
antigen challenge results in increased titers of circulating
pIgA1 antibodies with normal levels in mucosal secretions
[28, 29]. In addition, not only IgA+ cells but also polymeric
IgA are increasingly produced in the mucosa of IgAN
patients [30–32]. On the other hand, there is a report
demonstrating that there is a reduction in polymeric IgA
producing cells in duodenum [33]. Therefore, the crosstalk
between the mucosa and BM should be carefully discussed.
Furthermore, we should remember that the tonsil has
distinctive immunophenotypic characteristics and immune
statusincludinganatomicallocation,andpopulation,and/or
distribution of lymphocytes from the rest of the mucosal
immune system.
In a series of studies published almost 20 years ago, Van
Es et al. identiﬁed impaired IgA immune responses in the
mucosa-BM axis in IgAN [25, 29, 34, 35]. In the last decade,
clinical and experimental studies have revealed continued
traﬃcking of antigen-speciﬁc lymphocytes and antigen-
presenting cells between the mucosa and BM in humans
[6, 36]. The patterns of integrins and chemokine receptors
in these lymphocytes, including memory B cells and IgA
plasma cells, are slightly diﬀerent and depend on the site of
induction. This migration is directed by the local synthesis
of speciﬁc chemokines and appropriate adhesion/homing-
receptor engagement. There is increasing recognition for the
presence of a mucosa-BM axis in humans, and abnormalities
in this estimated axis may play an important role in the
development of IgAN [6].
3. Characteristicsof Abnormally
Glycosylated IgA in IgAN
It is now apparent that serum levels of galactose-deﬁcient
IgA1 (GdIgA1), mainly in IC forms, are often elevated in
IgAN patients [37–39]. Moldoveanu et al. recently demon-
strated, using a lectin-binding assay, that Caucasian IgAN
patients have increased levels of serum GdIgA1 [37].
The mesangial IgA deposits also display abnormal O-
glycosylation [40, 41] in IgAN. It is known that undergly-
cosylated IgA tends to be aggregated, indicating that the
polymeric formation of IgA1 may be, at least in part, based
on the aberrant glycosylation of IgA1 [42–44]. Furthermore,
pIgA has more capacity to activate mesangial cells than
monomeric IgA [45–49]. Accordingly, the involvement of
GdIgA in the pathogenesis of IgAN has been discussed
[2, 50, 51]. A recent study has shown that IgA1 secreted
by Epstein-Barr virus-immortalized B cells from peripheral
blood of IgAN patients was mostly polymeric, and had
galactose-deﬁcient sialylated O-glycans due to decreased β1,
3-galactosyltransferase (core1βGalT) activity, and increased
N-acetylgalactosamine-speciﬁc α2,6-sialyltransferase activ-
ity [38]. On the other hand, IgA1 produced by tonsillar
lymphocytesisalsoabnormallyglycosylatedinIgANpatients
[52–55]. These clinical ﬁndings taken together further
support the idea that the estimated mucosa–BM axis is the
location where B cells producing the nephritogenic GdIgA1
may traﬃc between tonsil and other organs via peripheral
blood in human IgAN [36].
Humans have two isotypes of IgA: IgA1 and IgA2. IgA1
contains O-glycosylation sites but IgA2 or murine IgA do
not [56]. Thus, the murine model does not include the
aberrant O-glycosylation involved in the human IgAN.
However, recent studies suggest that aberrant glycosylation
of N-glycans may be involved in the pathogenesis of murine
IgAN [57, 58], suggesting that aberrant modiﬁcations of
carbohydrates of serum IgA are involved in the development
of not only human but also murine IgAN, whether the
carbohydrates are O-glycans or N-glycans.
Renal biopsy and subsequent immunohistochemical
analysis of the renal tissue remains the gold standard for
diagnosing IgAN or evaluating the activity of acute lesions of
this disease; however, new sensitive, and reasonably speciﬁc,
non-invasive tests are emerging and may provide another
diagnosticapproach.Ourrecentstudyshowedthatreduction
of serum GdIgA1 after tonsillectomy was associated with
improvement of hematuria in certain IgAN patients (our
unpublished data). Since the primary abnormal clinical
manifestation in IgAN is recurring bouts of hematuria with
or without associated proteinuria [59], elevated circulating
levels of GdIgA1 is one of the most promising new tests for
diagnosis or activity of IgAN [37, 40, 41, 52–54].
However, Gharavi et al. have recently reported that
GdIgA1 levels were increased in 78% of sporadic IgAN
patients and in 25% of their blood relatives, although the
majority of relatives with abnormally glycosylated IgA1 were
asymptomatic [60]. This ﬁnding suggests that, in certain
cases, additional cofactors are required for development
of IgAN. In a recent publication, Suzuki and coworkersClinical and Developmental Immunology 3
described the characteristics of IgG autoantibodies to abnor-
mally glycosylated IgA1 secreted by immobilized B cells
derived from sporadic IgAN patients [61]. The serum levels
oftheseIgGautoantibodiescorrelatedcloselywiththedegree
of proteinuria, suggesting that IC formation of aberrantly
glycosylated IgA and glycan-speciﬁc IgG antibodies and
subsequent enlargement of their molecular mass may be
an additional cofactor required for full development of
the disease [62, 63]. In this regard, it is noteworthy that
the serum levels of IgA-IgG2a IC, but not of IgA, were
shown to correlate closely with the severity of glomerular
l e s i o n si nI g A N - p r o n em i c e[ 64]. In addition to the aberrant
glycosylation of IgA, similar mechanisms may underlie the
progression of both human and murine IgAN.
4. Mucosal Encounter of Nephritogenic
Exogenous Antigensin IgAN
The association of episodic macroscopic hematuria with
mucosal infections in IgAN is suggestive of changes to
the mucosal immune system in this disease, which may
include changes in antigen handling [6]. The results of
immunization studies in IgAN patients support that notion.
Mucosal immunization with neoantigen results in impaired
mucosalandsystemicIgAresponsesbutnormalIgGandIgM
responses [9, 10], suggesting that in IgAN there is mucosal
hyporesponsiveness to mucosal neoantigens. In contrast,
systemic and mucosal immunization with recall antigens
results in exaggerated systemic IgA responses with increased
and prolonged production of speciﬁc IgA [11, 12, 28, 65].
These results suggest that IgAN patients respond excessively
to recall antigens [6].
Common microbial and food or food-borne antigens
may also play a role in this process. Emancipator et al. [66]
demonstrated a pathogenic relationship between prolonged
mucosal antigenic exposure, formation of circulating IgA-
IC, and the development of GN. Those authors orally
immunized Balb/c mice with protein antigens and found a
signiﬁcant increase in speciﬁc IgA-producing plasma cells
in the lamina propria of bronchial and intestinal mucosae
coupled with a rise in circulating antigen-speciﬁc IgA and
mesangial deposits of IgA and J chain. Coppo et al. [67]h a v e
argued that altered mucosal processing of food antigens such
as gliadin, a lectin present in gluten, might be involved in the
inductionofthisdisease.HighserumlevelsofIgAantigliadin
have been reported in IgAN patients [68–70]. Coppo et al.
[71] have also demonstrated that mice orally immunized
with gliadin or ovalbumin developed glomerular injury with
intense glomerular IgA deposition, including antigliadin IgA
antibodies. In addition to intrinsic food antigens, food-
borne microbial contaminants may also provide an antigenic
stimulus in IgAN. Pestka et al. have demonstrated that
mice fed meals contaminated with deoxynivalenol developed
increased levels of serum IgA, circulating IgA-IC, mesangial
IgA deposition, and hematuria, all clinical features of human
IgAN [72–75]. However, in human IgAN, there are many
studies indicating that the levels of antibodies to food
antigens as well as microbial antigens are not any diﬀerent
from normal individuals [76, 77]. Therefore, we have to
carefullythinkdiﬀerencesinimmuneresponsestomucosally
encountered antigens, such as quality of antibodies or IC
between human and mouse.
5. Tonsillar B Cellsin the Generation of
Nephritogenic IgA in IgAN
Considered together, these studies suggest that mucosal
encounter with exogenous antigens derived from fungi, bac-
teria, and viruses could play a key role in the development of
IgAN. On the other hand, one can speculate that there is not
a single infectious or food antigen which has been uniformly
and convincingly associated with the development of IgAN.
It remains unclear, however, precisely how all these microbe-
relatedantigens interactwiththeIgA immune systemtotrig-
g e rd i s e a s e .I ti sa c t u a l l yd i ﬃcult to assess this question using
human samples alone. Therefore, we used animal models.
We were able to establish a spontaneous IgAN-prone murine
model [6, 78] and adopted it for our purpose. We found
that human and murine IgAN are regulated, at least partly,
by the same genes in addition to the same phenotype of
renal damage [78]. Growing evidence from studies of innate
immunity may provide a clue. Toll-like receptors (TLRs) are
a familyof pathogen recognition moleculesthat discriminate
self from nonself (pathogens) and activate suitable defense
mechanisms [79]. TLRs on antigen-presenting cells also
initiate and modulate adaptive immunity during infection
[80]. To assess these questions in reference to IgAN, we
examined the pathological roles of TLRs in this IgAN-prone
murine model [81]. An association study using an IgAN-
prone murine model showed that the progression of murine
IgAN was linked to signaling molecules of the TLR myeloid
diﬀerential protein 88 (MyD88) [81]. We also examined the
relationship between the TLR mRNA expression level in
splenocytes and disease activity, and found that the severity
of glomerular injury in this model was clearly linked only
to the degree of MyD88 and TLR9 expression in splenocytes
[81]. TLR9 recognizes microbial unmethylated DNA and
is expressed mainly by B cells and dendritic cells (DC)
in mucosa [82–84]. In fact, intranasal immunization with
CpG oligodeoxynucleotide (CpG-ODN), which is known
as a ligand for TLR9, aggravated glomerular damage with
elevation of the serum IgA level [81], conﬁrming that TLR,
and in particular TLR9, is involved in the pathogenesis of
murine IgAN.
We have also conﬁrmed that transfer of BM from the
IgAN-prone to wildtype control mice results in the develop-
ment of IgAN [64]. In contrast, BM transfer from wildtype
normal mice to the onset-prone mice abrogates glomerular
injury and mesangial deposition. These ﬁndings suggest that
BM may be a reservoir of memory cells capable of synthe-
sizing IgA with a propensity for mesangial deposition and
triggeringofGNinmurineIgAN,asinhumanIgAN[26,27].
Are these cells responsible for the nephritogenic IgA
production reserved only in BM? To approach the possi-
bility that these responsible cells are disseminated to other
lymphoid tissues, we transferred whole spleen cells from the
IgAN-prone mice into subacute combined immunodeﬁcient
(SCID) mice. BMT as well as cell transfer could reconstitute4 Clinical and Developmental Immunology
the murine IgAN in SCID mice, suggesting that the responsi-
ble cells may be also localized in systemic lymphoid organs
(Nakata et al., paper in preparation). Adoptive transfer
analyses in the same study showed that CD19+ cells are
necessary for the development of murine IgAN. CD19 is
expressed on follicular DC and B cells. Since CD19+ cell
transfer induced glomerular IgA deposition with elevation
of serum IgA even in SCID mice lacking T and B cells,
responsible CD19+ cells in this disease may be mainly B cells.
CD19 is present on B cells from earliest recognizable B-
lineage cells during development to B cell blast but is lost
on maturation to plasma cells [85]. On the other hand,
CD 138 is known to be a cell surface marker for plasma
cells [86]. Our recent study also showed that CD138+ cells
are seen in BM of reconstituted IgAN mice whereas those
from spleen did not induce glomerular IgA deposition or
glomerular lesions in Balb/c mice. Pre-B or immature B
cells in murine BM also express CD138; the cells lose their
capacity for CD138 expression after emigrating from BM,
but re-express it during the ﬁnal maturation to plasma cells
in peripheral lymphoid tissues or spleen. Therefore, the
responsible cells may be CD19+ Bc e l l sb u tn o tm a t u r eC D
138+ plasma cells, at least in murine IgAN. Furthermore,
reconstitutionofIgANbycelltransferofspleencellsdepleted
of the CD90+ pan T cell in both murine strains and cell
transfer of CD19+ cells in SCID mice indicates that the
responsible B cells link to the nephritogenic IgA in a T-
cell-independent manner. Our recent experimental study
using alymphoplasic (aly/aly)mice [87]furthersupports this
notion. Aly/aly mice have no secondary lymphoid tissues or
germinal center (GC) [88]. However, BMT from our IgAN-
pronemicealsoreconstitutedglomerularIgAdepositionand
glomerularlesionsinaly/alyrecipientmice[87].Thisﬁnding
suggests that somatic hypermutation in GC may not be
requiredfornephritogenicIgAproduction,atleastinmurine
IgAN. Accordingly, B cells related to the nephritogenic IgA
may mature in GC-independent and T-cell-independent
manners. Therefore, B-DC interaction should be carefully
evaluated. At the very least, both cells express TLR9 and are
key players in mucosal immunity.
Does TLR9 contribute to progression of human IgAN?
O u rp r e v i o u ss t u d yd e m o n s t r a t e dt h a tt w og e n o t y p e so f
TLR9 haveastrongassociationwiththeprogressionofIgAN,
indicating the involvement of TLR9 also in the pathogenesis
of human IgAN [81]. We demonstrated that the CC/CT
genotype in rs352139 and TT genotype in rs352140 could be
risk factors for the progression of IgAN. As mentioned pre-
viously, the tonsil can be a major mucosal site in the patho-
genesisofhumanIgAN.Humantonsilscontainrelativelyfew
IgA-producing cells, which in vitro secrete predominantly
monomeric and polymeric IgA1. The contribution of tonsil-
lar IgA1-producing cells to the total pool of IgA produced in
the human body must be minimal considering the absolute
number of cells in tonsils versus the mucosal tissues such as
gut, bone marrow, lymph nodes, and spleen. However, most
IgAN patients indeed showed a decrease in serum IgA after
tonsillectomy, in association with improvement of clinical
manifestations [89–91]. Moreover, tonsillar B cells in IgAN
patients produced more GdIgA1 and pIgA than those of
chronic tonsillitis or sleep apnea syndrome [52]. Further,
tonsillar CD19+ B cells in IgAN also showed downregulation
of core1βGalT expression, which is inversely correlated with
estimated glomerular ﬁltration rate [55].
Our recent study demonstrates that some IgAN patients
exhibited relatively high expression of tonsillar TLR9 mRNA
(theTLR9highgroup)andshowedanearlier,morecomplete
clinical remission than those with low TLR9 expression [92].
Patients whose serum IgA decreased more than the average
of enrolled IgAN patients after tonsillectomy (LargeΔIgA)
showed higher cumulative remission rates of proteinuria
than did the others (SmallΔIgA). CC/CT genotypes in
rs352139 [81] were more dominant and tonsillar TLR9
expressions were signiﬁcantly higher in LargeΔIgA than
in SmallΔIgA patients. Therefore, one can speculate that
tonsillar B-cell activation via TLR9 may be involved in the
production of the nephritogenic GdIgA1 in IgAN. In fact,
mononuclear cells from tonsils of IgAN patients treated
with CpG-DNA showed increased IgA, IFNγ, and the B-cell
activating factor of the tumor necrosis factor family (BAFF)
production [93]. On the other hand, Kodama et al. reported
that B1 cells, which produce IgA in T-cell-independent
manner, are increased in tonsils of IgAN patients [94]. Since
BAFF enhanced activation of TLR in activated B1 cells [95],
an increase of B1 cells may be important for pathogenesis of
IgAN. In this regard, it is noteworthy that recent microarray
analysis of tonsils from IgAN patients showed that tonsillar
expression of APOBEC2, known as a messenger molecule for
B cell development, is increased in IgAN [96].
Does mucosal DC expressing TLR9 play a role in the
pathogenesis of IgAN? To assess whether the TLR9 on
mucosal DC and B cells may play diﬀerent roles in pathogen-
esis of IgAN, we stimulated the IgAN-prone mice with cell-
speciﬁc CpG-ODN. Diﬀerent CpG-ODNs have been used
to study cell regulation by TLR9 in DC, and it has been
shown that CpG-A-ODN induces large amounts of IFN-
α in plasmacytoid DC, that CpG-B-ODN acts as a potent
stimulant of B cells, and that CpG-C-ODN functions as an
activator of both B cells and DC [97–99]. Surprisingly, each
CpG-ODNstimulationinduceddiﬀerentdiseasephenotypes
in IgAN-prone mice. Serum IgA levels increased in mice
treated with CpG-B-ODN, while elevation of serum IgA-
IgG2a ICs was found following administration of CpG-A-
ODN or CpG-C-ODN. The CpG-A-ODN group showed
mesangial proliferation, and CpG-B-ODN therapy induced
extracellular matrix expansion. The ﬂuorescent intensity of
glomerular IgA and IgG diﬀered in each group. Those data
suggest that, at least in murine IgAN, mucosal DC activation
via TLR9 may link the IgA/IgG IC formation to subsequent
proliferative glomerular damage.
6. Conclusion
As demonstrated here, clinical and experimental studies
indicate that responsible B cells in the tonsil may link to the
production of nephritogenic GdIgA1, which subsequently
induces pIgA1 and IgA/IgG IC formation. The B cells
seem to be activated by exogenous microbial antigens via
TLR9 in mucosa and traﬃc systemic organs, including BM.Clinical and Developmental Immunology 5
Therefore, surgical removal of tonsils may directly decrease
the number of the responsible B cells and their activation.
Additional steroid pulse therapy may thus further eliminate
the responsible B cells that are systemically disseminated.
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